—Mkt Cap: —P/E: —
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial…
Industry Peers
Health Care Equipment & SuppliesKey Statistics
Company
Market Cap—
Enterprise Value1.56B $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-287.86M $
Revenue/Share—
Last Price—
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees156
CountryUS
SectorHealthcare
IndustryHealth Care Equipment & Supplies
ISINUS20451W1018
Valuation
P/E (Trailing)—
P/E (Forward)-9.64
PEG—
EV/EBITDA-8.41
EV/Revenue—
P/S—
P/B22.18
EPS (TTM)-3.74
EPS (Forward)-1.43
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE544.70%
ROA-136.85%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-157.24M $
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-378.67M $
Net Debt/EBITDA2.04
Balance Sheet
Debt/Equity-0.66
Current Ratio1.29
Quick Ratio1.22
Book Value/Sh0.6230 USD
Cash/Share3.129 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)23.75 USD
Target Range13.00 USD – 65.00 USD
# Analysts16
Ownership
Shares Out.138.48M
Float106.97M
Insiders7.62%
Institutions68.02%
Short Interest
Short Ratio3.1d
Short % Float9.98%
Short % Out.9.85%
Shares Short13.64M
Short (prev mo.)10.17M
Technical
SMA 5012.70 USD
SMA 2008.676 USD
Beta2.53
S&P 52W Chg21.00%
Avg Vol (30d)—
Avg Vol (10d)2.66M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—